<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773630</url>
  </required_header>
  <id_info>
    <org_study_id>21-08-101</org_study_id>
    <nct_id>NCT00773630</nct_id>
  </id_info>
  <brief_title>A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Frankfurt Research Institute GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Frankfurt Research Institute GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to test whether Pletal ODT administered without water
      can be considered bioequivalent to Pletal administered with 200 ml water (both treatments
      being administered after fasting and at least 30 minutes prior to receiving a light
      breakfast) based on the standard pharmacokinetic variables.

      The secondary objective is to assess the effect of water and the effect of food on the
      administration of Pletal ODT based on standard pharmacokinetic variables.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve, maximal concentration (Cmax)</measure>
    <time_frame>1-2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum (tmax), Vss/f, CL/f)</measure>
    <time_frame>1-2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intake of Pletal 100 mg tablets dose together with 200 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intake of Pletal 100 mg ODT dose without water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intake of Pletal 100 mg ODT dose together with 200 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intake of Pletal 100 mg ODT dose without water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>100 mg Cilostazol</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy male and female subjects of Caucasian race

          2. able to read, to write and to fully understand German language

          3. having given voluntary written informed consent before first invasive screening
             examination procedure

          4. aged 18 to 45 years, inclusive

          5. BMI of 18 - 28 kg/m2

          6. good health as determined by medical history, physical examination, vital signs,
             electrocardiogram (ECG, serum/urine biochemistry and hematology)

        Exclusion Criteria:

          1. clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at
             time of dosing) drug hypersensitivity

          2. known hypersensitivity to one of the IMP substances

          3. severe digestive disorder or surgery of the digestive tract (except for appenÂ¬dectomy)

          4. clinically relevant renal disorders (albuminuria, chronic infections)

          5. clinically relevant hepatic disorders

          6. clinically relevant respiratory disorders

          7. clinically relevant cardiovascular disorders, especially any history of ventricular
             tachycardia, ventricular fibrillation or multifocal ventricular ectopics, or a history
             of additional risk factors for torsades de pointes (TdP) (e.g. heart failure,
             hypokalemia, congenital long QT-syndrome)

          8. diabetes mellitus and thyroid dysfunction or other endocrine disorders

          9. malignancy

         10. substance abuse or addiction (alcohol, illicit drugs) in the past 3 years

         11. neurologic or psychiatric illness

         12. known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6
             month) haemorrhagic stroke, surgery within the previous three months, proliferative
             diabetic retinopathy, poorly controlled hypertension)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarete Mueller, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAIPharma Deutschland GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AAIPharma Deutschland GmbH &amp; Co. KG</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>September 8, 2011</last_update_submitted>
  <last_update_submitted_qc>September 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

